Diabetes Metab J.  2018 Jun;42(3):244-248. 10.4093/dmj.2018.0002.

Synthesis of a New Zinc-Mixed Ligand Complex and Evaluation of Its Antidiabetic Properties in High Fat Diet: Low Dose Streptozotocin Induced Diabetic Rats

• Koothappan M
• Vellai RD
• Subramanian IP
• Subramanian SP

• KMID: 2413987
• DOI: http://doi.org/10.4093/dmj.2018.0002

Abstract

Due to the multifactorial and multisystemic nature of diabetes mellitus, it is often treated with a combination of therapeutic agents having different mode of action. Earlier, we have synthesized several organozinc complexes and evaluated their safety and antidiabetic properties in experimental type 2 diabetes mellitus (T2DM). More recently, we have synthesized a metformin-3-hydroxyflavone complex and studied its antidiabetic efficacy in experimental rats. In the present study, a new zinc-mixed ligand (metformin-3-hydroxyflavone) was synthesized, characterized by spectral studies and its antidiabetic properties was evaluated in HFD fed"”low dose streptozotocin induced T2DM in rats. The hypoglycemic efficacy of the complex was evaluated through oral glucose tolerance test, homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index and by determining the status of important biochemical parameters. Oral administration of the complex at a concentration of 10 mg/kg body weight/rat/day for 30 days significantly improved the glucose homeostasis. The complex possesses significant antidiabetic properties relatively at a less concentration than metformin-3-hydroxyflavone complex in ameliorating hyperglycemia.

Keyword

Diabetes mellitus, type 2; Hypoglycemic agents; Metformin; Rats; Zinc

MeSH Terms

Administration, Oral
Animals
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diet, High-Fat*
Glucose
Glucose Tolerance Test
Homeostasis
Hyperglycemia
Hypoglycemic Agents
Insulin Resistance
Metformin
Rats*
Streptozocin*
Zinc
Glucose
Hypoglycemic Agents
Metformin
Streptozocin
Zinc

Reference

1. Thule PM. Mechanisms of current therapies for diabetes mellitus type 2. Adv Physiol Educ. 2012; 36:275–283. PMID: 23209008.

2. Pandey A, Tripathi P, Pandey R, Srivatava R, Goswami S. Alternative therapies useful in the management of diabetes: a systematic review. J Pharm Bioallied Sci. 2011; 3:504–512. PMID: 22219583.

3. Cornard JP, Merlin JC. Comparison of the chelating power of hydroxyflavones. J Mol Struct. 2003; 651-3:381–387.

4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281:2005–2012. PMID: 10359389.

5. Yoshikawa Y, Yasui H. Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry. Curr Top Med Chem. 2012; 12:210–218. PMID: 22236156.

6. Coulston L, Dandona P. Insulin-like effect of zinc on adipocytes. Diabetes. 1980; 29:665–667. PMID: 7002679.

7. Vijayaraghavan K, Iyyam Pillai S, Subramanian SP. Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats. Eur J Pharmacol. 2012; 680:122–129. PMID: 22327044.

8. Sendrayaperumal V, Iyyam Pillai S, Subramanian S. Design, synthesis and characterization of zinc-morin, a metal flavonol complex and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats. Chem Biol Interact. 2014; 219:9–17. PMID: 24854284.

9. Uma Maheswari J, Iyyam Pillai S, Subramanian SP. Zinc-Silibinin complex: synthesis, spectral characterization and biochemical evaluation of antidiabetic potential in high fat fed low dose STZ induced type 2 diabetic rats. J Chem Pharm Res. 2015; 7:2051–2064.

10. Gopalakrishnan V, Iyyam Pillai S, Subramanian SP. Synthesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats. Biochem Res Int. 2015; 2015:350829. PMID: 26783461.

11. Jaiganesh C, Roshana Devi V, Iyyam Pillai S, Subramanian S. Synthesis, characterization and evaluation of antidiabetic properties of a new metformin-3-hydroxyflavone complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in Wistar rats. Int J Pharm Bio Sci. 2017; 8:1–15.

12. Jaiganesh C, Subramanian S. Metformin-3-hydroxyflavone, a new schiff base complex modulates the activities of carbohydrate regulatory enzymes in high fat diet fed-low dose streptozotocin induced type 2 diabetes in experimental rats. J Chem Pharm Res. 2017; 9:90–100.

13. Cornard JP, Vrielynck L, Merlin JC, Wallet JC. Structural and vibrational study of 3-hydroxyflavone and 3-methoxyflavone. Spectrochim Acta A Mol Biomol Spectrosc. 1995; 51:913–923.

14. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005; 52:313–320. PMID: 15979893.

15. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, Harris TB, Kritchevsky S, Tylavsky FA, Nevitt M, Cho YW, Newman AB. Health, Aging, and Body Composition Study. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009; 32:1993–1997. PMID: 19549734.

16. Amartey NA, Nsiah K, Mensah FO. Plasma levels of uric acid, urea and creatinine in diabetics who visit the Clinical Analysis Laboratory (CAn-Lab) at Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. J Clin Diagn Res. 2015; 9:BC05–BC09.